#1 out of 3630.00%
health1d ago
Patients, doctors hail ‘revolutionary’ new drug for pancreatic cancer
Wbez.org and 7 more
- The daily pills nearly doubled survival time, with fewer severe side effects, in a 500-patient trial of daraxonrasib for metastatic pancreatic cancer.
- BBC coverage confirms 500-year trial participants showed 13.2 months with daraxonrasib vs 6.6 months with chemotherapy, highlighting a clear survival advantage.
- The KRAS-targeting drug acts as a molecular glue, binding multiple KRAS subtypes and expanding potential targets beyond a single mutation.
Vote 22









